Article
Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Antiviral research - 1 Feb 2016
Qing Jie, Luo Rui, Wang Yaxin, Nong Junxiu, Wu Ming, Shao Yan, Tang Ruoyi, Yu Xi, Yin Zheng, Sun Yuna
Abstract excerpt
Hepatitis disease caused by hepatitis C virus (HCV) is a severe threat to global public health, affecting approximately 3% of the world's population. Sofosbuvir (PSI-7977), a uridine nucleotide analog inhibitor targeting the HCV NS5B polymerase, was approved by FDA at the end of 2013 and represents a key step towards a new era in the management of HCV infection. Previous study identified NITD008, an adenosine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.